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Question: Is preoperative physiotherapy cost-effective in reducing postoperative pulmonary complications
(PPC) and improving quality-adjusted life years (QALYs) after major abdominal surgery? Design: Cost-
effectiveness analysis from the hospitals’ perspective within a multicentre randomised controlled trial with
concealed allocation, blinded assessors and intention-to-treat analysis. Participants: Four hundred and
forty-one adults awaiting elective upper abdominal surgery attending pre-anaesthetic clinics at three public
hospitals in Australia and New Zealand. Interventions: The experimental group received an information
booklet and a 30-minute face-to-face session, involving respiratory education and breathing exercise
training, with a physiotherapist. The control group received the information booklet only. Outcome
measures: The probability of cost-effectiveness and incremental net benefits was estimated using
bootstrapped incremental PPC and QALY cost-effectiveness ratios plotted on cost-effectiveness planes and
associated probability curves through a range of willingness-to-pay amounts. Cost-effectiveness modelling
utilised 21-day postoperative hospital cost audit data and QALYs estimated from Short Form-Six Domain
health utilities and mortality to 12 months. Results: Preoperative physiotherapy had 95% probability of
being cost-effective with an incremental net benefit to participating hospitals of A$4,958 (95% CI 10 to 9,197)
for each PPC prevented, given that the hospitals were willing to pay $45,000 to provide the service. Cost-
utility for QALY gains was less certain. Sensitivity analyses strengthened cost-effectiveness findings.
Improved cost-effectiveness and QALY gains were detected when experienced physiotherapists delivered
the intervention. Conclusions: Preoperative physiotherapy aimed at preventing PPCs was highly likely to
be cost-effective from the hospitals’ perspective. For each PPC prevented, preoperative physiotherapy is likely
to cost the hospitals less than the costs estimated to treat a PPC after surgery. Potential QALY gains require
confirmation. Trial registration: ACTRN12613000664741. [Boden I, Robertson IK, Neil A, Reeve J,
Palmer AJ, Skinner EH, Browning L, Anderson L, Hill C, Story D, Denehy L (2020) Preoperative physio-
therapy is cost-effective for preventing pulmonary complications after major abdominal surgery: a
health economic analysis of a multicentre randomised trial. Journal of Physiotherapy -:-–-]
© 2020 Australian Physiotherapy Association. Published by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction suggest that methods to minimise hospital costs, whilst main-With 300 to 500 operations per 100,000 people annually,
abdominal surgery is the most common major surgery type
performed in developed countries, with volumes increasing at 2
to 5% per year.1–3 Patients having surgery account for a quarter of
hospital bed days, yet accrue half of all hospital costs.4 Existing
large volumes, high costs and the increasing need for surgery. Published by Elsevier B.V. This is ataining or enhancing service quality, are important to ensure
long-term sustainability of hospital funding. Reducing post-
operative complications could be one such method. Complications
after abdominal surgery are the principal driver for increased
costs, with higher expenditure on pharmaceuticals, diagnostic
testing and lengths of stay in the intensive care unit and surgical
ward.5n open access article under the CC BY-NC-ND license (http://creativecommons.org/lice
2 Boden et al: Cost-effectiveness of preoperative physiotherapyAmong the most common complications after major abdominal
surgery are postoperative pulmonary complications (PPCs),5,6 which
range from mild atelectasis to severe hospital-acquired pneumonia
and respiratory failure.6 PPCs independently increase costs following
major colorectal,7 upper gastrointestinal8 and renal surgery.9 Even
mild PPCs are associated with increased hospital utilisation.6,10 PPCs
are strongly associated with worse mortality6–11 and health-related
quality of life (HRQoL).12 A recent multicentre randomised
controlled trial,11 the Lung Infection Prevention Post Surgery Major
Abdominal with Pre-Operative Physiotherapy (LIPPSMAck-POP) trial,
replicated previous findings,13 confirming that a single preoperative
physiotherapy education and training session halves PPC incidence
with a number needed to treat of seven. Patients place high priority
on preventing pneumonia after surgery, value preoperative physio-
therapy and prefer individual face-to-face sessions.14 Yet despite
strong effectiveness,11,13 patient preference14 and international
consensus that preventing PPC should be a key feature of perioper-
ative care,6 preoperative physiotherapy is seldom provided.15,16 Un-
certainty surrounding the economic cost/benefit of preoperative
physiotherapy may be preventing the implementation of this highly
efficacious patient-centred intervention.
Therefore, the research question for this planned within-trial
health economic analysis was:
Is preoperative physiotherapy cost-effective in reducing post-
operative pulmonary complications and improving quality-
adjusted life years (QALYs) after major abdominal surgery?
Methods
Design
This planned health economic evaluation was conducted within a
multicentre, parallel-group, pragmatic, randomised controlled trial
involving three diverse (rural, regional and metropolitan)
government-funded hospitals in Australia and New Zealand11 and
reported in accordance with Consolidated Health Economic Evalua-
tion Reporting Standards17 (see Appendix 1 on the eAddenda).
Detailed descriptions of the study design and methods are avail-
able11,18 and briefly outlined here. Participants were randomly
assigned via sealed opaque envelopes. Independent audit confirmed
appropriate randomisation.11 Participants, outcome assessors, post-
operative physiotherapists, doctors, nurses, hospital administrators
and statisticians were unaware of group assignment.
Participants
Inclusion criteria were: English speaking, age  18 years, and
attending a pre-anaesthetic assessment clinic within 6 weeks of
elective major abdominal surgery. Immobile patients and those
having organ transplantation or hernia repair were excluded.
Interventions
At the pre-anaesthetic clinic all participants were seen by a
physiotherapist for a 30-minute standardised social, functional and
respiratory assessment. They were provided with a booklet contain-
ing information about postoperative pneumonia risk and prevention
with early ambulation and breathing exercises. Control group par-
ticipants received no further information or training from the
physiotherapist.
Experimental group participants received an additional 30-minute
one-on-one physiotherapy education and training session about the
effect of anaesthesia and surgery on mucociliary clearance and lung
volumes, and the consequences of bacterial stagnation in the lungs. They
were educated that self-directed postoperative deep breathing and
coughingexercisesarevital to reduce theriskofpneumoniaafter surgery
and directed to commence these immediately upon regaining con-
sciousness and to perform 30 repetitions hourly until fully ambulant.Preoperative interventions were delivered by physiotherapists
with experience ranging from new graduates to. 10 years practice in
acute care and surgery ward settings. Postoperative early ambulation
was standardised and no additional prophylactic respiratory physio-
therapy was provided.
Outcome measures
The cost-effectiveness of preoperative physiotherapy to prevent
PPC and improve QALYs after major abdominal surgery was assessed
using an incremental cost/utility analysis conducted from the hospital
perspective as payer of the service. Incremental cost-effectiveness
ratios were determined by dividing the difference between the
experimental and control groups in net mean hospital costs per
participant by the differences in PPC rates 14 days after surgery and
QALYs 12 months from surgery.
Cost-effectiveness model inputs: 21-day hospital costs
Hospital costs for each treatment arm comprised the costs of
providing the preoperative physiotherapy protocol and the costs of
hospital resource use in the first 21 days after surgery.
Preoperative physiotherapy costs were estimated using salary rates
in 2018 Australian dollars individualised to the experience level of
each treating physiotherapist and costed to the maximum level within
a band (see Appendix 2 on the eAddenda). Overheads of 25% were
added (eg, superannuation, professional development, training,
administration and backfill). New Zealand dollars were converted to
Australian dollars using December 2018 exchange rates. Costings were
based on control group participants receiving a 30-minute physio-
therapy session and experimental group participants receiving 60
minutes. Booklet costs and clinic room hire were added (see Appendix
2 on the eAddenda). Administration costs to process referrals or co-
ordinate bookings were not incorporated, as all participants attended
an established clinic with an existing infrastructure.
Postoperative downstream hospital costs were estimated using a
detailed patient-level costings model. Units of hospital activity were
counted prospectively and daily by blinded trial assessors using the
written and electronic medical records until 21 days after surgery or
hospital discharge, whichever occurred first. Audited hospital activity
included: bed days and location (ICU, surgical ward or residential
rehabilitation); mechanical and non-invasive ventilation hours;
antibiotic prescriptions; modes and days of oxygen therapy; number
and type of imaging and pathology tests; and medical consultations
outside standard rounds. These items of hospital activity were chosen
as their consumption is associated with PPC.5–11 Duration of hospital
stay was cross-validated using hospital databases. Tariffs for items of
hospital activity were derived from Australian healthcare authorities
(see Appendix 2 on the eAddenda) and converted to 2018 Australian
dollars using consumer price indices 2013 to 2018, as listed by the
Australian Bureau of Statistics. Discounting of costs was not necessary
as follow-up was within 12 months.17
Cost-effectiveness model inputs: quality-adjusted life years
QALYs were estimated using health utilities converted from
HRQoL measures assessed with the Short-Form 36-item question-
naire (SF-36), a valid and responsive patient-reported outcome after
abdominal surgery.19 HRQoL data acquisition started from the 79th
participant following receipt of funding for research assistant activ-
ities. Baseline responses were measured at the preoperative clinic
within 6 weeks of surgery then repeated by phone with a masked
assessor at 6 to 8 weeks after surgery. Postoperatively, if patients
were unable to be contacted, a standardised letter, SF-36 question-
naire and self-addressed return-paid envelope were posted. Forms
not returned within 2 weeks were considered lost to follow-up. Ac-
quired SF-36 scores were converted to SF-six domains (SF-6D) health
utilities using commercial softwarea, providing values from 0 (death)
to 1 (full health).20 The SF-6D is valid and reliable for estimating
health utilities after abdominal surgery.21
Research 3The typical trajectory of HRQoL after major elective colorectal and
upper gastrointestinal surgery is of an immediate postoperative
deterioration with a return to baseline HRQoL at 2 to 6 months and
remaining stablewithinpresurgeryHRQoL levels to at least 1 year after
surgery.21–25 Therefore, baseline preoperativeHRQoL scoreswere used
to estimate each participant’s 12-month health utility values as an
alternative to reassessing HRQoL at 12 months directly from partici-
pants.26 QALYs were calculated by multiplying the reported health
utility state by the number of weeks spent in this health state. For
participants who died, QALY estimates were censored to this date.26
Calculations using the linear change area-under-the curve method26
were applied to two time periods: baseline to 6 weeks (direct value)
and 6weeks to 1 year (estimated value). These valueswere summed to
obtain 12-month QALYs. The maximum QALY for this study was 1,
representing full health over the entire year. See Appendix 3 on the
eAddenda for detailed descriptions of QALY calculations.
Cost-effectiveness
A cost-effectiveness analysis considers the additional cost of a new
intervention relative to the improvement in outcomes gained
compared with providing usual care or an alternative intervention.
This is calculated by dividing the between-group net cost difference
by the differences in treatment effects (eg, between-group difference
in costs/difference in absolute risk reduction in PPC).27,28 This is
termed an incremental cost-effectiveness ratio.
To manage fundamental heterogeneity in hospital costs, health
utilities and reduced statistical power regarding secondary outcomes,
bootstrapping statistical techniques are considered essential in esti-
mating cost-effectiveness within randomised controlled trials.27,28
Bootstrapping is where the original trial’s economic and clinical out-
comes are run through a mathematical model using the variance in the
original data to simulate hypothetical results if the same trial was
conductedmany hundreds or thousands of times over. These simulated
cost-effectiveness ratios better represent the wide range of possible
cost-effectiveness outcomes that could be expected in the population
and not just from that sampled in the trial. These simulated cost-
effectiveness ratios are then graphed on a cost-effectiveness plane
(Figure 1A). The cost-effectiveness plane has four quadrants. The
quadrant in which the cost-effectiveness ratios predominantly fall
contributes to the decision by the purchaser of the intervention about
whether or not the intervention is cost-effective and provides value for
money. Interventions where all simulated cost-effectiveness ratios fallFigure 1. A and B. Cost-effectiveness plot and cost-effectiveness acceptability curve of preo
complications.into the south-east quadrant (ie, net cost savings and improved out-
comes comparedwithusual care or control) are always considered cost-
effective.28 Yet, because hospital cost accounting is highly variable, this
lack of precision leads to estimated cost-effectiveness ratios often being
scattered across a number of quadrants. This reflects the statistical
possibility that in somecircumstances the intervention ismore effective
thanstandard carebut comesat agreaternet cost (north-east quadrant).
Additional costs required by a hospital to fund a new treatment
can be considered worthwhile if the improvement in clinical outcome
is valued enough to pay more for it.27 This is known as the
willingness-to-pay amount.29 Willingness to pay is an arbitrary figure
regarded by the payer (eg, self-funded patient, hospital or govern-
ment) as the amount of money considered worthwhile to pay for each
unit of improvement in a desired outcome. For example, 1,000 sur-
veyed Australians were willing to pay $82,000 (95% CI 77,000 to
88,000; 2007 data adjusted to 2018 Australian dollars) from their
own funds for a hypothetical treatment if it improved their QALY.30
From an Australian government perspective, although there is no
explicit willingness-to-pay threshold currently stated, all new medi-
cations approved for public funding have cost less than $75,000 per
QALY gain (2003 data adjusted to 2018 Australian dollars).31
Whereas the literature discussingwillingness-to-pay thresholds for
QALY improvements is extensive, no opinion has been published
regarding what is considered a reasonable amount by a hospital to
spend on PPC prevention. For the specific purposes of estimating the
cost-effectiveness of preoperative physiotherapy in this trial, it was
hypothesised that a hospital would be willing to pay to prevent PPC as
long as it costs less than the treatment costs of a PPC. The additional
cost burden independentlyattributed toPPCs in a 2008 study involving
46,000 major colorectal surgery patients across 600 US hospitals was
$45,000 per PPC (2008US dollars adjusted to 2018 Australian dollars).7
This is currently the most methodologically robust assessment of
additional hospital costs directly attributable to PPCs.
Due to the statistical chance of a new intervention costing more
than usual care and the lack of certainty surrounding a hospital’s
willingness to pay to prevent PPCs or improve QALYs,
cost-effectiveness is best determined using a cost-effectiveness
acceptability curve.28 This method provides the probability of an
intervention being cost-effective over a range of willingness-to-pay
amounts. The threshold on how much money is worthwhile
spending on improving a clinical outcome will vary from hospital to
hospital depending on the value placed on improving the target
outcome and the extensive heterogeneity in the processes for fundingperative physiotherapy versus information booklet to reduce postoperative pulmonary
4 Boden et al: Cost-effectiveness of preoperative physiotherapynew services. A cost-effectiveness acceptability curve provides in-
formation to the decision-maker to guide this choice.
Due to the uncertainty surrounding an agreed willingness-to-pay
amount for PPC prevention, the return on investment for a hospital
paying for a preoperative physiotherapy service was calculated as an
alternative measure of cost-effectiveness (net difference in cost be-
tween groups / cost of intervention). In circumstances where the
mean incremental cost-effectiveness ratio indicated improved out-
comes with cost savings, the incremental net benefit32 to the hospital
was also calculated (incremental net benefit = (willingness to pay 3
difference in treatment effects) – difference in costs between groups).
A higher value equals greater cost-effectiveness.
Data analysis
This study was primarily powered to detect a treatment effect on
PPC.11,18 Bootstrapping methods were employed to manage the
inherently limited power to detect significant differences in secondary
outcomes, including costs and QALYs. To manage missing HRQoL data,
characteristics of participantswith complete datawere comparedwith
those with missing data. Fully conditional specification and predictive
mean matching were used to make multiple imputations with chain
equations, assuming that data were missed at random,33 and adjusted
for baseline utility to account for regression to the mean.34
Costs of hospital activity for individual items and the aggregate
total were compared between-groups using adjusted mixed-effects
linear regression analyses with logarithmic transformation of
skewed data. Within-group and between-group differences for
HRQoL, health utility and QALYs were analysed using adjusted
repeated-measures mixed-effects linear regression. All outcomes
were assessed by intention to treat. Bootstrapping of 5,000 paired
incremental cost-effectiveness ratio estimates were performed and
graphed on a cost-effectiveness plane and mean differences and
confidence intervals were calculated.
Exploratory sub-group analyses were conducted by considering
effects and costs separately in participants seen by experienced
physiotherapists ( 10 years) or less-experienced physiotherapists.
This was to analyse if the possible benefit of improved PPCs and
mortality reduction detected when preoperative education was
delivered by an experienced physiotherapist11 is outweighed by the
increased costs of employing a more experienced clinician.
Two sensitivity analyses were conducted. Cost-effectiveness ana-
lyses involve a number of assumptions and value judgements in con-
structingmodels for determining hospital costs and QALYs. Sensitivity
analyses consider the stability of health economic findings by assess-
ing the variation in results when areas of uncertainty are changed. This
provides confidence in the primary findings or suggests areas
requiring further research.17,27 First, government hospital episode-of-
care costs were used to compare groups. These costs were indepen-
dently generated by hospital administrators and incorporated all
direct (eg, theatre time, personnel, equipment and medications) and
ancillary costs (eg, cleaning, catering and building overheads) for the
whole hospital episode of care from admission to hospital discharge.
This is the primary process of hospital cost accounting in Australia.35
Second, only health utilities where a full set of preoperative and
postoperative HRQoL data were collected directly from a patient were
considered to calculate QALYs.
All outcomes, including costs and HRQoL, were adjusted for im-
balances in age, respiratory comorbidity and surgical category
detected at baseline.11 Analyses were conducted using commercial
softwareb by the trial’s statistician. Methodology, data, results and
interpretation were validated by two independent health economists.Results
Characteristics of participants
Detailed participant characteristics have been published already.11
Median age was 65 years (IQR 52 to 75) and most were male (61%).Their surgical procedures were oncological (69%), major colorectal
(49%), urological (26%), or upper gastrointestinal/hepatobiliary pro-
cedures (24%). Operations were generally . 2 hours (64%) via upper
midline (49%) or subcostal (18%) incisions.
Flow of participants
From June 2013 to August 2015, 504 patients were eligible for
inclusion, with 441 (88%) randomly assigned: 219 to the control
group and 222 to the experimental group.11 Nine (2%) participants
were withdrawn. Data for PPC, mortality and hospital costs were
available for all 432 participants. Baseline characteristics of the cohort
and treatment effects for PPC and mortality have been published
already.11 The flow diagram of HRQoL data acquisition is shown in
Appendix 4 on the eAddenda. Preoperative HRQoL was obtained in
315 participants (73%). Missing preoperative HRQoL was propor-
tionally higher in the experienced physiotherapist sub-group (Table 1
on the eAddenda) as HRQoL acquisition did not start until the 79th
participant, when only experienced physiotherapists were actively
recruiting. There was a 69% (217/315) follow-up rate 6 weeks after
surgery. Follow-up was similar between groups (114/160 (71%)
experimental; 103/155 (66%) control) and between sub-groups. Par-
ticipants who acquired a postoperative complication or had an
extended hospital stay were more likely to have missing 6-week
postoperative HRQoL data (Table 1 on the eAddenda).
Cost-effectiveness model inputs: 21-day hospital costs
Across the whole cohort the primary cost contributors for the first
21 postoperative hospital days were surgical ward (64%), ICU bed days
(19%) and diagnostic testing and imaging (7%), as shown in Table 2. The
cost of the intervention inclusive of salary, overheads, room hire and
consumables was an additional $52 (95% CI 51 to 53) per participant
compared with control group participants, or $27 (95% CI 26 to 28)
when using available clinic rooms. Following surgery, experimental
group participants consistently tended to consume fewer post-
operative hospital resources across all assessed items compared with
control participants (Table 2). Individual items with a 95% confidence
interval estimate closest to the statistically significant cost saving
were: usage of oxygen therapy, sputum cultures, blood cultures and
antibiotics prescribed for respiratory complications. The between-
group difference in adjusted total 21-day hospital costs was $458
saved (95% CI24,490 to 4,697) favouring the experimental group. This
mean estimate of net savings provided a return on investment of
approximately 800% ($8 saved by the hospital for every $1 spent on
physiotherapy to provide education and breathing exercise training to
patients before surgery), although the precision of this single-trial
estimate was low, as shown by the wide confidence intervals.
Cost-effectiveness model inputs: quality-adjusted life years
Adjusted within-group and between-group HRQoL are reported in
Table 3 on the eAddenda. Six weeks following surgery, physical do-
mains had declined up to 30% in both groups, whilst emotional and
mental health domains were unaffected. No between-group differ-
ences were detected in HRQoL at 6 weeks or QALYs at 12 months (MD
0.020, 95% CI 20.008 to 0.045).
Cost-effectiveness for PPC reduction
As previously reported,11 preoperative physiotherapy halved PPC
incidence (27% versus 13%, adjusted hazard ratio 0.48, 95% CI 0.30 to
0.75). A large proportion of incremental cost effectiveness ratios fall
in the south-east quadrant of the cost-effectiveness graph (Figure 1A),
giving a 60% probability that the preoperative intervention was either
cost-neutral or cost-saving to the hospitals (Figure 1B). At a
willingness-to-pay threshold of $45,000 (the estimated additional
cost to the hospital to treat patients with PPC),7 preoperative phys-
iotherapy had a 95% probability of being cost-effective to prevent PPC,
giving an incremental net benefit to the hospitals of $4,958 saved
Table 2
21-day hospital costs and effects of preoperative physiotherapy versus standard care.
Parameter Costs/unit of use Whole cohort
(n = 432)
Experimental
(n = 218)
Control
(n = 214)
Difference between groups
Experimental minus control
Mean (SD)
units
Mean (SD)
costs
Mean (SD)
units
Mean (SD)
costs
Mean (SD)
units
Mean (SD)
costs
Mean (95% CI) p value
Costs
Preoperative physiotherapy
physiotherapist salary $45 to 55/hr 0.75 (0.25) $41 (17) 1 (0) $52 (10) 0.5 (0) $25 (1) $27 (26 to 28) ,0.0001
room hire $50/hr 0.75 (0.25) $38 (13) 1 (0) $50 (0) 0.5 (0) $25 (0) $25 (25 to 25) ,0.0001
booklet $5/booklet 1 (0) $5 (0) 1 (0) $5 (0) 1 (0) $5 (0) $0 (0 to 0) 1.0
Hospital ward use
ICU/HDU stay $3,000/d 1.4 (2.8) $4,188 (8,438) 1.3 (2.9) $3,867 (8,633) 1.5 (2.7) $4,514 (8,242) 2$647 (22,244 to 950) 0.43
surgical ward stay $1,500/d 9.5 (8.5) $14,153 (12,710) 9.2 (8.5) $13,728 (12,774) 9.7 (8.4) $14,586 (12,554) 2$858 (23,254 to 1,538) 0.55
sub-acute stay $800/d 1.0 (5.4) $779 (4,292) 0.82 (4.5) $659 (3,630) 1.1 (6.1) $902 (4,879) 2$243 (21,055 to 569) 0.55
Ventilation support
mechanical ventilation $1,500/d 0.25 (1.4) $377 (2,057) 0.22 (1.2) $330 (1,727) 0.28 (1.6) $425 (2,349) 2$95 (2484 to 294) 0.63
non-invasive ventilation $500/d 0.04 (0.3) $21 (143) 0.04 (0.3) $18 (135) 0.05 (0.3) $23 (151) 2$5 (232 to 22) 0.72
high-flow oxygen $100/d 0.18 (0.9) $36 (130) 0.16 (0.9) $33 (124) 0.20 (1.0) $40 (136) 2$7 (232 to 18) 0.54
standard oxygen $20/d 3.0 (2.8) $60 (57) 2.8 (2.7) $56 (53) 3.2 (3.0) $65 (60) 2$9 (220 to 2) 0.11
Imaging and pathology
sputum cultures $50/test 0.3 (0.8) $14 (40) 0.22 (0.6) $11 (32) 0.33 (0.9) $17 (47) 2$6 (214 to 2) 0.13
blood cultures $50/test 0.3 (1.1) $17 (55) 0.25 (0.9) $12 (46) 0.42 (1.3) $21 (63) 2$9 (219 to 1) 0.11
all other pathology $30/test 40.4 (55.5) $1,213 (1,666) 38.0 (58.3) $1,139 (1,749) 43.0 (52.6) $1,289 (1,578) 2$150 (2465 to 165) 0.35
chest X-rays $70/test 2.0 (3.2) $142 (231) 1.8 (2.8) $129 (214) 2.2 (3.5) $155 (247) 2$26 (270 to 18) 0.24
chest CTs $450/test 0.1 (0.4) $42 (162) 0.07 (0.3) $31 (122) 0.12 (0.4) $53 (195) 2$22 (253 to 9) 0.17
all other imaging $100/test 1.1 (2.8) $110 (278) 1.0 (3.2) $104 (326) 1.2 (2.2) $116 (219) 2$12 (265 to 41) 0.63
Antibiotics
respiratory indication $100/d 1.2 (3.0) $121 (297) 0.94 (2.8) $94 (286) 1.5 (3.1) $149 (309) 2$55 (2111 to 1) 0.05
all other indications $100/d 2.9 (4.4) $169 (311) 1.8 (3.4) $181 (335) 1.6 (2.8) $156 (285) $25 (240 to 84) 0.42
Medical visits
out of round visits $300/visit 1.9 (2.8) $573 (854) 1.8 (2.7) $544 (817) 2.0 (3.0) $603 (891) 2$59 (2221 to 103) 0.43
MET calls $1,000/call 0.12 (0.5) $116 (493) 0.11 (0.5) $106 (473) 0.13 (0.5) $127 (513) 2$21 (2114 to 72) 0.55
Total 21-day costs, unadjusted $22,201 (24,142) $21,143 (24,290) $23,282 (23,998) 2$2,139 (26,706 to 2,428) 0.19
Targeted costs model, adjusteda $21,867 (24,455) $22,325 (21,724) 2$458 (24,697 to 4,490) 0.42
Sensitivity analysis: whole episode-of-care costs
a
$31,829 (26,845) $30,900 (25,165) $32,767 (28,469) 2$1,867 (26,946 to 3,212) 0.47
Effects
pulmonary complicationsa 27 (12%) 58 (27%) 210% (214 to 25) 0.001
12-month mortalitya 16 (7%) 23 (11%) 21.6% (24.5 to 3.7) 0.46
QALY, imputed data set, unadjusted 0.671 (0.19) 0.642 (0.19) 0.029 (0.002 to 0.055) 0.015
QALY, imputed data set, adjustedab 0.667 (0.19) 0.647 (0.19) 0.020 (20.008 to 0.045) 0.08
Sensitivity analysis: QALY complete cases onlyab 0.656 (0.22) 0.659 (0.20) 20.003 (20.05 to 0.04) 0.89
All costs are in 2018 Australian dollars. Raw unadjusted cost data are mean (SD) and mean difference (95% confidence interval) with p-values estimated using mixed effects linear regression.
ICU = intensive care unit, HDU = high dependency unit, CT = computerised tomography, MET = medical emergency team, QALY = quality-adjusted life years.
a Adjusted for age, respiratory comorbidity, surgical category using multiple regression and Poisson regression.
b Adjusted for baseline utility.
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pay threshold of $18,000 there was an 80% probability of cost-
effectiveness. See Appendix 5 in eAddenda for graphed incremental
net benefits for willingness-to-pay amounts from $0 to $60,000.
Cost-utility for QALY improvement
Bootstrapped estimates indicated that preoperative physiotherapy
was likely to improve QALYs 12 months after surgery; however, due
to the spread of incremental cost-effectiveness ratios across both the
south-east and north-east quadrants (Figure 2A), there is uncertainty
if this comes at an additional cost or is cost saving to the hospital.
Given a willingness-to-pay threshold of $50,000 per one QALY gain,
preoperative physiotherapy had 73% probability of being considered
value for money (Figure 2B), with an incremental net benefit
favouring the experimental group of $1,458 (95% CI 23,490 to 5,697).
Sub-group analyses
Within the experienced physiotherapist sub-group (see Table 4 on
the eAddenda), the mean adjusted hospital cost savings favouring the
experimental intervention were stronger ($1,156 saving per partici-
pant, 95% CI 25,300 to 6,937) with an 80% probability of cost-
effectiveness at a willingness-to-pay threshold of $10,000
(Figure 2B). Large and significant 12-month QALY gains were also
detected in the experimental group treated by more experienced
physiotherapists (adjusted MD 0.051, 95% CI 0.015 to 0.088, p = 0.01),
with a 90% probability of improving QALYs within a willingness-to-
pay threshold of $50,000 (Figures 2A and 2B).
Sensitivity analyses
Government episode-of-care costings were $31,829 per partici-
pant (SD 26,845), with the adjusted between-group cost differences
more strongly favouring the experimental group than the targeted
costing model (Table 2). Preoperative physiotherapy had a 95%
probability of being cost-effective in preventing PPC at a willingness-
to-pay threshold of $45,000, giving an incremental net benefit to
hospitals of $6,367 (95% CI 1,288 to 11,446). When QALYs were
calculated using health utilities from complete cases only, cost-utility
was reduced, giving an incremental net benefit of $308 (95%
CI 24,640 to 4,547) per QALY gained.Figure 2. A and B. Cost-utility plot and cost-effectiveness acceptability curve of preoperaDiscussion
A PPC is a high-cost event with severe negative consequences to
patients and hospitals.4–10 A PPC is . 15 times more common than a
cardiac complication, has similar effects on in-hospital mortality, and
is responsible for more than doubling the baseline cost of abdominal
surgery, costing a hospital approximately $45,000 to treat.7 Large
randomised controlled trials have found that a single preoperative
physiotherapy education and training session reduces PPC incidence
by 25 to 75%.11,13 By reducing PPC risk after major abdominal surgery,
respiratory physiotherapy has been associated with reduced hospital
length of stay,36 antibiotic usage36 and reintubation rates.37 However,
the LIPPSMAck-POP trial is the first with a detailed audit of hospital
resource use and a thorough health economic analysis. When ac-
counting for the cost of introducing the service, there was a 60%
likelihood that preoperative physiotherapy resulted in overall cost
savings to participating hospitals through reductions in downstream
hospital resource use. In circumstances where a net cost may be
incurred to provide preoperative physiotherapy to prevent PPCs, it is
reasonable to consider that hospitals would be willing to pay for this
as long as it costs less than treating a PPC. This trial found that if a
hospital is willing to pay $18,000 to prevent one PPC (ie, less than half
the cost of a PPC), preoperative physiotherapy is 80% likely to be cost-
effective.
A consistent signal of reduced costs of downstream hospital
resource use was found in the experimental group participants, with
an estimated return on investment of $8 saved postoperatively for
every $1 spent on preoperative physiotherapy. Given the inevitable
wide confidence intervals in a cost-benefit analysis based on a single
trial, the level of precision around this estimate is low. A recent
prehabilitation trial that halved postoperative complication rates
following high-risk major abdominal surgery38 reported wide vari-
ance in costing data and a non-significant difference in postoperative
hospital costs favouring the experimental group ($536 net saving,
95% CI 21,626 to 3,113; costs converted to Australian dollars at 2018
exchange rates).39 Randomised controlled trials rarely have large
enough sample sizes to overcome the wide variance in patient-level
resource use and costs and are generally unable to detect primary
significance in cost measures. A cost-benefit analysis (simple com-
parison in net costs between a new intervention and usual care or
control) not only requires exceptionally large clinical trials to defi-
nitely prove a fiscal benefit from a new intervention, but also does nottive physiotherapy versus information booklet to improve quality-adjusted life years.
Research 7incorporate societal or consumer beliefs on the value of incurring
additional costs for improved benefits.27
A cost-effectiveness analysis considers the relative relationship
between treatment costs and how effective the treatment is in
improving the desired outcome. This value is then placed in the
context of how much a consumer would be prepared to pay in order
to gain an improvement in the desired outcome. For this trial, most
cost-effectiveness ratios fell in the south-east quadrant of the cost-
effectiveness plane, indicating an overall mean cost saving to hospi-
tals and reduced risk of PPCs for patients when compared with usual
care. The probability that preoperative physiotherapy is cost-neutral
or entirely cost-saving to the hospitals was 60% (Figure 1B). Howev-
er, due to the very wide standard deviations in hospital costings, the
statistical chance of preoperative physiotherapy costing the hospital
more than is saved in downstream ward costs cannot be discounted.
If the benefit gained in reducing PPC incidence and improving QALYs
after major surgery are important to a hospital, they may be willing to
pay to instigate a preoperative physiotherapy service to achieve this.
Within this trial there was a 5% chance that the preoperative phys-
iotherapy service cost the hospitals more to prevent one PPC than the
estimated $45,000 it costs to treat a PPC. The probability of preop-
erative physiotherapy being cost-effective to prevent PPCs at a
reasonable cost was therefore 95%. The consistent signal of individual
hospital activity savings favouring the experimental group and in-
dependent hospital episode-of-care costings demonstrating a stron-
ger reduction in costs strengthens the likelihood that preoperative
physiotherapy truly reduces downstream hospital costs and consti-
tutes a dominant strategy in preventing PPCs.
Improved value for money appears to be gained by hospitals if
experienced physiotherapists provide the intervention, with greater
PPC reductions,11 reduced postoperative mortality,11 large significant
QALY gains and a stronger signal towards reducing downstream
hospital costs. Even when accounting for the additional costs of
employing a more experienced physiotherapist, there was an 80%
probability of cost-effectiveness at a willingness-to-pay threshold of
less than a quarter of the estimated cost of treating a PPC,7 with a
possible return on investment in the order of 1,800% (ie, $18 saved for
every $1 spent on an experienced physiotherapist). Further research
is required to confirm these experience-related effects, to determine
what qualities and attributes regarding treatment from an experi-
enced practitioner may make it more effective and whether these
factors are trainable in others.
Although the probability of cost-effectiveness for preoperative
physiotherapy to prevent PPCs is strong, there is less certainty sur-
rounding its ability to improve HRQoL and QALYs at a reasonable cost.
Sensitivity analysis of complete QALY data indicated fragility around
the result. There are some limitations to the trial that could explain
this. HRQoL data acquisition started after a fifth of all patients had
been recruited. This incomplete baseline data set and a 31% missing
6-week follow-up rate led to imputed measures comprising 50% of all
health utility results. As a consequence, the trial’s HRQoL estimates
have inherent uncertainty and may not truly represent the whole
population. Countering this concern, the large declines detected in
HRQoL physical domains but not mental health domains within 2
months of surgery were congruent with other studies.12,39
Patients who develop postoperative complications tend to have
poorer HRQoL compared with patients without complications.12 An
intervention that halves PPCs after major abdominal surgery could
improveHRQoL trajectory at 6weeks. Thiswas not detected in this trial,
perhaps due to inherently reduced power for this secondary outcome
and/or a response bias. Participants who suffered a postoperative
complication were more likely to be missed to follow-up, minimising
power to detect a treatment response of preventing PPCs on short-term
HRQoL. Whilst the imputed data set demonstrated an improved signal
towards improvements, these findings are uncertain and need to be
confirmed in a trial with adequate follow-up and power.
The time point of data collection could also have impacted the
sensitivity of detecting an effect on HRQoL. After major abdominal
surgery, HRQoL tends to normalise around 2 months.21–25 Assessmentof HRQoL at an earlier time point (eg, 4 weeks) may have more
sensitivity at detecting possible differences associated with preven-
tion of postoperative complications. Improvements in 4-week post-
operative SF-36 physical domains have been reported following an
intensive preoperative exercise and behavioural therapy intervention
that halved postoperative complications.39 A multimodal interven-
tion targeting physical fitness might impact postoperative HRQoL
physical domains more than a unimodal intervention targeting a
single postoperative complication, as studied in this trial.
This study was conducted in Australia and New Zealand. The best es-
timate of costs to hospitals attributable to a PPC after abdominal surgery is
currently derived froma largeUS-based study.7 To the authors’ knowledge
this is the most methodologically robust data in this field; however, US
costs might not be directly comparable with hospitals operating within a
universal public healthcare system. Cost-effectiveness interpretations
could be improved if comparative PPC costs from similar healthcare
funding structures in the LIPPSMAck-POP trialwere available. Additionally,
this health economic analysis does not include the costs of the additional
physiotherapy required if participants contracted a PPC, hospital costs
beyond21days, ormedical and societal costs followinghospital discharge,
including primary healthcare use, hospital readmissions and productivity.
It is possible that the experimental intervention could have better cost-
effectiveness if these outcomes were included. Providing some support
for this assumption is theobservation thatwhole episode-of-care cost data
demonstrated a between-group cost difference four times the magnitude
of the restricted cost accounting modelling.
The decision on whether or not something is cost-effective comes
down to the purchaser or consumer (ie, the hospital) deciding if the
benefit (ie, a reduction in PPC or an improvement in QALY) is worth
paying a certain amount to achieve. The determination of the cost-
effectiveness of preoperative physiotherapy will be a valuation made
by each hospital based on local ideals to prevent PPCs and improve
patient QALYs after surgerywhilst considering the strength of evidence,
generalisability to a local context and the reported probabilities of cost-
effectiveness. The LIPPSMAck-POP trial found a 60% probability that
preoperative physiotherapy was cost-neutral or entirely cost-saving in
preventing PPCs. At this estimate, millions of dollars of healthcare
funding could be saved if preoperative physiotherapy is instigated as
standard care to the 50million patients who undergo major abdominal
surgery every year in Europe, Australia and the USA alone.1–3 Alterna-
tively, there is a 40% probability that reducing the PPC rate and
improving QALYs after surgery with preoperative physiotherapy would
require additional funding over and above standard care. In this case,
there is a 95% probability that preoperative physiotherapy is cost-
effective if a hospital is willing to pay anywhere up to $45,000 for the
service to prevent one PPC with an incremental net benefit of $4,958
(95% CI 10 to 9,197) in the hospital’s favour for each PPC prevented.
This is the first multicentre randomised controlled trial investi-
gating PPC prophylaxis with a comprehensive analysis of post-
operative hospital use and a robust integrated health economic
analysis. Preoperative physiotherapy is a highly efficacious treatment
that halves the incidence of a serious postoperative complication,11,13
is valued by patients,14 is non-harmful,11 and is highly likely to be
cost-effective from a hospital’s perspective in preventing PPCs after
major abdominal surgery.What was already known on this topic: Before major
abdominal surgery, a single physiotherapy session involving
education and training markedly reduces the incidence of post-
operative pulmonary complications. Uncertainty about the cost-
effectiveness of preoperative physiotherapy may be making
some hospitals reluctant to institute this intervention.
What this study adds: Preoperative physiotherapy aimed at
preventing postoperative pulmonary complications is highly likely
to be cost-effective from the hospitals’ perspective. Improved
cost-effectiveness and quality-adjusted life-year gains were
detected when experienced physiotherapists delivered the
intervention.
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